Dear Almighty, page-3

First 3 Last

Share
Profile

Follow
Dr.Who

4,679 Posts.

145

12/04/16

14:18

Post #: 17482906
Share

Originally posted by Cato ↑

Well well my friend, I'm positive still you come here everyday and read most texts..

I'm not sure if you hold your previous shares or if you sold all, or maybe part.

Something I'm sure, and that's the reason I'm writing to you., Not to squeeze or make you feel bad..Im not such kind of guy, but mostly because life is learning curve.

You saw in the "other share" we both hold such a disaster to believe in "board talks".
Board must present results..when they begin talk is a bad sign...

Who does, dont need talk too much ,the results are enough.

I remember very well when I told you(and was not advise) to just stop to invest and believe and be more reserved and carefull something was not going ok...
The share was 3. I told you also at 1 and also at 0.50

Now, must remain the question.. and at 0.20 ?

Well... sounds the trend is break 0.20 considering the announcement expected on 30/4 ( 30/4?) and looks like a long long way in a daily drops of 2-10% per day.
Again not advise but sincere view... carefull... double triple, thinking to bet yes, can be the "solution" but can be also the funeral of most capital.

I did that and when things goes wrong for sure trying to "save" the losses you loose much more.

Obvious nobody knows the future.. At least if you do something do, 100% conscient if the things goes wrong..
We all be temp to jump and try(including me) ... but that can be the final recipie for disaster..

Cato

Expand

Cato, "Obvious nobody knows the future.."?????

The Doc knows the future

SGH Price at posting: 21.5¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program